J.Jpn. Surg. Soc.. 81(6): 494-504, 1980
Original article
COMBINED CHEMOTHERAPY FOR GASTRIC CANCER
－CLINICAL AND EXPERIMENTAL RESEARCH－
|
Department of Surgery, School of Medicine, Keio University, Tokyo, Japan (Director: Prof. Osahiko Abe) Yong Hwa Moon |
Chemotherapeutic effects were evaluated mainly by T/C ratio (% of treated group by control group) of tumor weight on the 4th week after tumor inoculations, additionally by growth curve and histological findings of the tumors.
Degree of tumor regression had quite a good correlation with doses of intraperitoneally injected MMC or FT-207 which represented that these tumors are excellent materials for experimental combined cancer chemotherapy with the both drugs.
The minimum effective doses of MMC to St-4, St-15, and Co-3 were identified as 0.2 mg/kg, 2 mg/kg, and 1 mg/kg and FT-207 as none, 60 mg/kg, and 90 mg/kg. Half of minimum effective doses of MMC and FT-207 were administered as combined chemotherapy and synergistic action on St-4, additive action on St-15, and Co-3 were observed.
MMC and FT-207 were given to patients who had gastrectomy for gastric cancer during May 1975―November 1976 at Keio University Hospital.
Patients were divided into 2 groups by random selection:
Group A (only MMC 20 + 10 mg after operation)
Group B (same dose cf MMC as group A + FT-207 600―800 mg daily per os)
On comparison of these two groups, the results obtained were as follows:
1) Three year actuarial survival rates were 65.8% in group A and 85.5% in group B.
2) Three year relative survival rate of group B in poorly differentiated type, large sized tumor (over 6 cm in diameter) and INF γ are significantly higher than those of group A.
3) No significant differences in side effects were observed between two groups.
To read the PDF file you will need Adobe Reader installed on your computer.